Explore our blogs on various markets

Summary. Roche has officially initiated the global rollout of Lunsumio® (mosunetuzumab) for the treatment of adult patients with third-line and beyond relapsed or refractory follicular lymphoma (FL). The fixed-duration, off-the-shelf, T-cell engaging bispecific antibody has already been commercially used in over 2,400 patients, according to company data, with significant adoption across major oncology markets....

Zomedica Pharmaceuticals has released a new and improved canine cortisol assay for its TRUFORMA point-of-care diagnostic platform. . The assay allows veterinarians to diagnose Cushing’s syndrome and Addison’s disease within minutes, using a simple in-clinic process. . Previously, such diagnoses required shipping blood samples to external labs and waiting one or two days for results...

Discover the top 5 generative AI tools transforming drug discovery with faster molecule design, target prediction, and real-world pharma applications.. Generative AI has almost transformed how drug discovery works today. In the last five years, it has gone from being a research experiment to a practical tool used by biotech firms and pharmaceutical companies around the world. ...

The market for generic immunology drugs in the Asia-Pacific (APAC) region is witnessing rapid expansion, driven by increasing healthcare access, rising chronic disease prevalence, and cost-containment measures by governments. . As more biologics go off-patent, pharma companies are moving quickly to introduce affordable generic and biosimilar alternatives across key APAC markets.. If you are planning to enter or expand in this space, pricing is one of the most critical levers for success...

In 2025, the pharmaceutical industry is seeing major changes in drug development, pricing, and delivery. AI is speeding up R&D, GLP-1 drugs are redefining obesity treatment, and precision medicine is becoming standard. . This guide breaks down the top trends shaping pharma this year, with real examples and their impact on healthcare and business....

Artificial Intelligence (AI) is changing modern healthcare by helping doctors make faster, smarter decisions. From diagnosing diseases to personalizing treatments and reducing paperwork, AI is making care more accurate and efficient. . With the global AI healthcare market expected to reach nearly $96 billion by 2033, it's clear that AI is no longer just a future trend—it’s a key part of today’s medical systems. ...

AI is changing how we discover new medicines. Instead of testing each idea in a lab, AI studies massive medical data to quickly find the most promising drug candidates. . This speeds up research, lowers costs, and improves success rates...

Several large language models (LLMs) are already being used or evaluated by pharmaceutical companies and health tech teams. From accelerating drug discovery to streamlining regulatory submissions and enhancing patient education, LLMs are redefining how life sciences teams work with data, documents, and decisions.. Unlike traditional AI systems, LLMs can read, understand, and generate natural language at scale, making them ideal for navigating the complexity of biomedical literature, clinical protocols, compliance guidelines, and real-world evidence....

Generative AI is helping doctors and scientists design personalized medicine faster and more accurately. These AI tools use medical, genetic, and clinical data to create treatment plans, drugs, and predictions that match an individual’s unique biology.. Researchers and biotech companies are now using generative AI (GenAI) models to improve patient care...

AI and ML imaging tools are now central to drug discovery. These systems process cell images to detect drug effects, predict safety, and optimize compounds. In this news article, you will find how AI and ML-based imaging are reshaping drug discovery in 2025....